ArticlePlastic and reconstructive surgery. Global open2021
Oral Beta-blocker in Problematic Infantile Hemangioma.
Article in Plastic and reconstructive surgery. Global open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 3 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One of the most common benign vascular endothelial tumors is infantile hemangioma. These lesions are commonly found in the head and neck, and sometimes it is a challenge to decide the method of treatment if the lesions are problematic hemangiomas, interfering with function or aesthetic appearance. This study reports a case of girl aged 3 years, 7 months, diagnosed with periorbital infantile hemangioma that was successfully treated with oral propranolol in specific doses and gradual tapering off dose. The patient had marked involution of the lesion with no significant side effects after starting her treatment at the age of 4 months, for a total of 13 months with no reported rebound growth after almost 2 years since the termination of treatment. Oral beta-blockers can be used safely in treatment of problematic infantile hemangioma as a single modality, without any surgical intervention.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.